Recruitment of β-Catenin by Wild-Type or Mutant Androgen Receptors Correlates with Ligand-Stimulated Growth of Prostate Cancer Cells

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Molecular Endocrinology

• Publication date

  2004-10-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1210/ME.2003-0436
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Glycogen Synthase Kinase-3β Activity Is Required for Androgen-Stimulated Gene Expression in Prostate Cancer

  2004cited by this paper
• Differential modulation of androgen receptor transcriptional activity by the nuclear receptor co-repressor (N-CoR).

  2004cited by this paper
• Antiandrogen effects of mifepristone on coactivator and corepressor interactions with the androgen receptor.

  2004cited by this paper
• Synergistic effects of coactivators GRIP1 and beta-catenin on gene activation: cross-talk between androgen receptor and Wnt signaling pathways.

  2004cited by this paper
• Agonist-antagonist induced coactivator and corepressor interplay on the human androgen receptor.

  2003cited by this paper
• Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663.

  2003cited by this paper
• Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome.

  2003cited by this paper
• A Direct β-Catenin-independent Interaction between Androgen Receptor and T Cell Factor 4*

  2003cited by this paper
• Nuclear receptors: a rendezvous for chromatin remodeling factors.

  2003cited by this paper
• Glucocorticoid receptor antagonism by cyproterone acetate and RU486.

  2003cited by this paper
• Regulation of Androgen Receptor Activity by the Nuclear Receptor Corepressor SMRT*

  2003cited by this paper
• Functional localization and competition between the androgen receptor and T-cell factor for nuclear β-catenin: a means for inhibition of the Tcf signaling axis

  2003cited by this paper
• Mutation of the androgen receptor at amino acid 708 (Gly-->Ala) abolishes partial agonist activity of steroidal antiandrogens.

  2003cited by this paper
• Review of the in vivo functions of the p160 steroid receptor coactivator family.

  2003cited by this paper
• β-Catenin-related Anomalies in Apoptosis-resistant and Hormone-refractory Prostate Cancer Cells

  2003cited by this paper
• β-Catenin Binds to the Activation Function 2 Region of the Androgen Receptor and Modulates the Effects of the N-Terminal Domain and TIF2 on Ligand-Dependent Transcription

  2003cited by this paper
• The amino terminus of the human AR is target for corepressor action and antihormone agonism.

  2002cited by this paper
• AR and ER interaction with a p21-activated kinase (PAK6).

  2002cited by this paper
• Molecular biology of the androgen receptor.

  2002cited by this paper
• Phosphatidylinositol 3-Kinase/Akt Stimulates Androgen Pathway through GSK3β Inhibition and Nuclear β-Catenin Accumulation*

  2002cited by this paper
• The Androgen Receptor Can Promote β-Catenin Nuclear Translocation Independently of Adenomatous Polyposis Coli*

  2002cited by this paper
• Structural characterization of a subtype-selective ligand reveals a novel mode of estrogen receptor antagonism

  2002cited by this paper
• T‐cell factors: turn‐ons and turn‐offs

  2002cited by this paper
• Antiandrogens: selective androgen receptor modulators.

  2002cited by this paper
• Evaluation of ligand-dependent changes in AR structure using peptide probes.

  2002cited by this paper
• Bicalutamide Functions as an Androgen Receptor Antagonist by Assembly of a Transcriptionally Inactive Receptor*

  2002cited by this paper
• Linking β-Catenin to Androgen-signaling Pathway*

  2002cited by this paper
• Liganded androgen receptor interaction with beta-catenin: nuclear co-localization and modulation of transcriptional activity in neuronal cells.

  2002cited by this paper
• In vitro evidence for complex modes of nuclear β-catenin signaling during prostate growth and tumorigenesis

  2002cited by this paper
• Ligand-dependent inhibition of β-catenin/TCF signaling by androgen receptor

  2002cited by this paper
• Identification and characterization of ART-27, a novel coactivator for the androgen receptor N terminus.

  2002cited by this paper
• Inhibition of the dihydrotestosterone-activated androgen receptor by nuclear receptor corepressor.

  2002cited by this paper
• RU486-induced Glucocorticoid Receptor Agonism Is Controlled by the Receptor N Terminus and by Corepressor Binding*

  2002cited by this paper
• Stabilization of β-catenin induces lesions reminiscent of prostatic intraepithelial neoplasia, but terminal squamous transdifferentiation of other secretory epithelia

  2002cited by this paper
• Coactivator/corepressor ratios modulate PR-mediated transcription by the selective receptor modulator RU486

  2002cited by this paper
• The specificity of interactions between nuclear hormone receptors and corepressors is mediated by distinct amino acid sequences within the interacting domains.

  2001cited by this paper
• Caveolin-1 Interacts with Androgen Receptor

  2001cited by this paper
• Tumor Suppressor Pten Inhibits Nuclear Accumulation of β-Catenin and T Cell/Lymphoid Enhancer Factor 1–Mediated Transcriptional Activation

  2001cited by this paper
• Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer.

  2000cited by this paper
• Effects of antiandrogens on chromatin remodeling and transcription of the integrated mouse mammary tumor virus promoter.

  2000cited by this paper
• Detection and analysis of β‐catenin mutations in prostate cancer

  2000cited by this paper
• Beta-catenin affects androgen receptor transcriptional activity and ligand specificity.

  2000cited by this paper
• FXXLF and WXXLF Sequences Mediate the NH2-terminal Interaction with the Ligand Binding Domain of the Androgen Receptor*

  2000cited by this paper
• Distinguishing androgen receptor agonists and antagonists: distinct mechanisms of activation by medroxyprogesterone acetate and dihydrotestosterone.

  1999cited by this paper
• The CoRNR motif controls the recruitment of corepressors by nuclear hormone receptors

  1999cited by this paper
• Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist.

  1999cited by this paper
• Effects of new 17α-hydroxylase/C17,20-lyase inhibitors on LNCaP prostate cancer cell growth in vitro and in vivo

  1999cited by this paper
• Activation Function 2 in the Human Androgen Receptor Ligand Binding Domain Mediates Interdomain Communication with the NH2-terminal Domain*

  1999cited by this paper
• Mechanisms of androgen receptor activation and function.

  1999cited by this paper
• The Androgen Receptor Amino-Terminal Domain Plays a Key Role in p160 Coactivator-Stimulated Gene Transcription

  1999cited by this paper
• Functional interactions of the AF-2 activation domain core region of the human androgen receptor with the amino-terminal domain and with the transcriptional coactivator TIF2 (transcriptional intermediary factor2).

  1998cited by this paper
• The Nuclear Corepressors NCoR and SMRT Are Key Regulators of Both Ligand- and 8-Bromo-Cyclic AMP-Dependent Transcriptional Activity of the Human Progesterone Receptor

  1998cited by this paper
• The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen.

  1998cited by this paper
• Nuclear receptor-binding sites of coactivators glucocorticoid receptor interacting protein 1 (GRIP1) and steroid receptor coactivator 1 (SRC-1): multiple motifs with different binding specificities.

  1998cited by this paper
• Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-γ

  1998cited by this paper
• A nuclear receptor corepressor modulates transcriptional activity of antagonist-occupied steroid hormone receptor.

  1998cited by this paper
• β-Catenin Mutations in Human Prostate Cancer

  1998cited by this paper
• Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen.

  1997cited by this paper
• The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT.

  1997cited by this paper
• Functional characterization of mutant androgen receptors from androgen-independent prostate cancer.

  1997cited by this paper
• Interaction between the Amino- and Carboxyl-terminal Regions of the Rat Androgen Receptor Modulates Transcriptional Activity and Is Influenced by Nuclear Receptor Coactivators*

  1997cited by this paper
• A signature motif in transcriptional co-activators mediates binding to nuclear receptors

  1997cited by this paper
• Molecular basis of agonism and antagonism in the oestrogen receptor

  1997cited by this paper
• RU486 (mifepristone): mechanisms of action and clinical uses.

  1997cited by this paper
• Functional in vivo interaction between the amino-terminal, transactivation domain and the ligand binding domain of the androgen receptor.

  1997cited by this paper
• TIF2, a 160 kDa transcriptional mediator for the ligand‐dependent activation function AF‐2 of nuclear receptors.

  1996cited by this paper
• A canonical structure for the ligand-binding domain of nuclear receptors

  1996cited by this paper
• GRIP1, a novel mouse protein that serves as a transcriptional coactivator in yeast for the hormone binding domains of steroid receptors.

  1996cited by this paper
• Sequence and Characterization of a Coactivator for the Steroid Hormone Receptor Superfamily

  1995cited by this paper
• Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer.

  1995cited by this paper
• Androgen receptor defects : Historical, clinical, and molecular perspectives

  1995cited by this paper
• Androgen Receptor Antagonist versus Agonist Activities of the Fungicide Vinclozolin Relative to Hydroxyflutamide (*)

  1995cited by this paper
• Ligand-induced Conformational Alterations of the Androgen Receptor Analyzed by Limited Trypsinization

  1995cited by this paper
• Evidence for an Anti-parallel Orientation of the Ligand-activated Human Androgen Receptor Dimer (*)

  1995cited by this paper
• Antiandrogens inhibit human androgen receptor‐dependent gene transcription activation in the human prostate cancer cells LNCaP

  1994cited by this paper
• Androgen receptor phosphorylation, turnover, nuclear transport, and transcriptional activation. Specificity for steroids and antihormones.

  1992cited by this paper
• Switching agonistic, antagonistic, and mixed transcriptional responses to 11 beta-substituted progestins by mutation of the progesterone receptor.

  1992cited by this paper
• The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens.

  1992cited by this paper
• A single amino acid that determines the sensitivity of progesterone receptors to RU486.

  1992cited by this paper
• Domains of the human androgen receptor involved in steroid binding, transcriptional activation, and subcellular localization.

  1991cited by this paper
• Transcriptional activation and nuclear targeting signals of the human androgen receptor.

  1991cited by this paper
• A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens.

  1990cited by this paper
• Aberrant response in vitro of hormone‐responsive prostate cancer cells to antiandrogens

  1989cited by this paper
• The human androgen receptor: domain structure, genomic organization and regulation of expression.

  1989cited by this paper
• Androgen‐dependent growth regulation of and release of specific protein(s) by the androgen receptor containing human prostate tumor cell line LNCaP

  1986cited by this paper
• Comparison of the antiandrogenic/androgenic activities of flutamide, cyproterone acetate and megestrol acetate.

  1985cited by this paper

• Nuclear receptor NURR1 functions to promote stemness and epithelial-mesenchymal transition in prostate cancer via its targeting of Wnt/β-catenin signaling pathway

  2024cites this paper
• Modulation of the canonical Wnt activity by androgen signaling in prostate epithelial basal stem cells

  2023cites this paper
• Endocrine Disruptors and Prostate Cancer

  2022cites this paper
• Nuclear Receptor Coregulators in Hormone-Dependent Cancers

  2022cites this paper
• Mechanism of Anti-Cancer Activity of Curcumin on Androgen-Dependent and Androgen-Independent Prostate Cancer

  2020cites this paper
• Interplay Between SOX9, Wnt/β-Catenin and Androgen Receptor Signaling in Castration-Resistant Prostate Cancer

  2019cites this paper
• Molecular and functional characterization of Arabidopsis thaliana VPNB1 gene involved in plant vascular development.

  2018cites this paper
• The effects of flutamide on cell-cell junctions in the testis, epididymis, and prostate.

  2018cites this paper
• Clinical Implications of Osmolytes in Various Human Diseases

  2017cites this paper
• Aberrant TGF-&bgr; Signaling Drives Castration-Resistant Prostate Cancer in a Male Mouse Model of Prostate Tumorigenesis

  2017cites this paper
• A Tale of Two Signals: AR and WNT in Development and Tumorigenesis of Prostate and Mammary Gland

  2017cites this paper
• Thyroid in a jar: towards an integrated in vitro testing strategy for thyroid-active compounds

  2015cites this paper
• Galeterone Prevents Androgen Receptor Binding to Chromatin and Enhances Degradation of Mutant Androgen Receptor

  2014cites this paper
• The promise and perils of HDAC inhibitors in neurodegeneration

  2014cites this paper
• Molecular pathways and targets in prostate cancer

  2014cites this paper
• Prostate cancer bone metastases acquire resistance to androgen deprivation via WNT5A-mediated BMP-6 induction

  2014cites this paper
• Wnt signaling in castration-resistant prostate cancer: implications for therapy.

  2014influential citation
• Beyond Androgen Deprivation

  2014cites this paper
• Targeting bone physiology for the treatment of metastatic prostate cancer.

  2013cites this paper
• Enzalutamide, an androgen receptor signaling inhibitor, induces tumor regression in a mouse model of castration‐resistant prostate cancer

  2013cites this paper
• Prostate Cancer Progression to Androgen Independent Disease: The Role of the PI3K/AKT Pathway

  2013cites this paper
• Role of WNT7B-induced Noncanonical Pathway in Advanced Prostate Cancer

  2013cites this paper
• Androgen Action, Wnt Signaling, and Prostate Tumorigenesis

  2013cites this paper
• β-Catenin Is Required for Prostate Development and Cooperates with Pten Loss to Drive Invasive Carcinoma

  2013cites this paper
• Effects of platelet-activating factor and its differential regulation by androgens and steroid hormones in prostate cancers

  2013cites this paper
• Androgen Receptor Activity Is Affected by Both Nuclear Matrix Localization and the Phosphorylation Status of the Heterogeneous Nuclear Ribonucleoprotein K in Anti-Androgen-Treated LNCaP Cells

  2013cites this paper
• TCF/LEFs and Wnt signaling in the nucleus.

  2012cites this paper
• Wnt/β-catenin signalling in prostate cancer

  2012cites this paper
• Testosterone: The state-of-the-art in the development of selective androgen receptor modulators

  2012cites this paper
• Role of androgen receptor polyQ chain elongation in Kennedy's disease and use of natural osmolytes as potential therapeutic targets

  2012cites this paper
• Androgen‐induced PSA expression requires not only activation of AR but also endogenous IGF‐I or IGF‐I/PI3K/Akt signaling in human prostate cancer epithelial cells

  2011cites this paper
• Role of the androgen receptor CAG repeat polymorphism in prostate cancer, and spinal and bulbar muscular atrophy.

  2011cites this paper
• Prostate Cancer Progression to Androgen Independent Disease: The Role of the Wnt/β-Catenin Pathway

  2011influential citation
• Androgen Receptor Biology in Prostate Cancer

  2010cites this paper
• Cross-regulation of signaling pathways: an example of nuclear hormone receptors and the canonical Wnt pathway.

  2010cites this paper
• Dehydroepiandrosterone administration or G{alpha}q overexpression induces {beta}-catenin/T-Cell factor signaling and growth via increasing association of estrogen receptor-{beta}/Dishevelled2 in androgen-independent prostate cancer cells.

  2010cites this paper
• 5α‐Dihydrotestosterone (DHT) retards wound closure by inhibiting re‐epithelialization

  2009cites this paper
• Unique Effects of Wnt Signaling on Prostate Cancer Cells: Modulation of the Androgen Signaling Pathway by Interactions of the Androgen Receptor Gene and Protein with Key Components of the Canonical Wnt Signaling Pathway

  2009cites this paper
• Selective androgen receptor modulators as function promoting therapies

  2009cites this paper
• Pharmacological Values of Medicinal Mushrooms for Prostate Cancer Therapy: The Case of Ganoderma Lucidum

  2008cites this paper
• Crosstalk between the androgen receptor and beta-catenin in castrate-resistant prostate cancer.

  2008cites this paper
• Evaluation of a variant in the transcription factor 7‐like 2 (TCF7L2) gene and prostate cancer risk in a population‐based study

  2008cites this paper
• Structural basis for nuclear receptor corepressor recruitment by antagonist-liganded androgen receptor

  2008cites this paper
• Wnt signaling: the good and the bad.

  2008cites this paper
• Androgen-mediated Control of the Cyclin D1-RB Axis: Implications for Prostate Cancer

  2008cites this paper
• Somatic Genetic Changes in Prostate Cancer

  2008cites this paper
• Gene Profiling Analysis of Androgen Receptor Mediated Function

  2008cites this paper
• Emerging Targets of the GnRH Receptor: Novel Interactions with Wnt Signalling Mediators

  2008cites this paper
• Wnt/β-Catenin Signaling Is a Component of Osteoblastic Bone Cell Early Responses to Load-bearing and Requires Estrogen Receptor α*

  2007cites this paper
• Glyceraldehyde-3-phosphate Dehydrogenase Enhances Transcriptional Activity of Androgen Receptor in Prostate Cancer Cells*

  2007cites this paper
• Gene therapy approach in prostate cancer cells using an active Wnt signal.

  2007cites this paper
• Estrogen Receptors Critically Regulate Bones’ Adaptive Responses to Loading

  2007cites this paper
• Inactivation of Apc in the mouse prostate causes prostate carcinoma.

  2007cites this paper
• Androgen receptor coregulators and their involvement in the development and progression of prostate cancer

  2007cites this paper
• Activity of androgen receptor antagonist bicalutamide in prostate cancer cells is independent of NCoR and SMRT corepressors.

  2007cites this paper
• Androgen receptor corepressors and prostate cancer.

  2006cites this paper
• Epigenetics of prostate cancer: beyond DNA methylation

  2006cites this paper
• Androgen receptor regulates nuclear trafficking and nuclear domain residency of corepressor HDAC7 in a ligand-dependent fashion.

  2006cites this paper
• Roles and regulation of Wnt signaling and β-catenin in prostate cancer

  2006cites this paper
• The Glucocorticoid Receptor Represses Cyclin D1 by Targeting the Tcf-β-Catenin Complex*

  2006cites this paper
• PTEN and GSK3β: key regulators of progression to androgen-independent prostate cancer

  2006cites this paper
• Multifaceted interaction between the androgen and Wnt signaling pathways and the implication for prostate cancer

  2006cites this paper
• Interaction of nuclear receptors with the Wnt/beta-catenin/Tcf signaling axis: Wnt you like to know?

  2005cites this paper
• Regulation of AR and (beta)-Catenin Signaling by Pin 1 in Prostate Cancer

  2005cites this paper
• Involvement of {beta}-catenin and unusual behavior of CBP and p300 in glucocorticosteroid signaling in Schwann cells.

  2005cites this paper
• Beta-catenin is involved in insulin-like growth factor 1-mediated transactivation of the androgen receptor.

  2005cites this paper